PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
Otitis media (OM) is a common middle ear disease that is treated with antibiotics. However, over-prescription of antibiotics heightens the risk of antibiotic resistance. Here, we report the development and testing of a new cold microplasma (CMP) device to treat OM, and demonstrate the translation for in vivo use in a chinchilla animal model. In vitro nontypeable Haemophilus influenzae bacterial and biofilm samples and ex vivo tissue specimens were evaluated for inactivation and injury. CMP-induced effects on any infectious symptoms (middle ear fluid, biofilms) were longitudinally observed with OCT. This represents the first application of CMP treatments for OM therapy.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
The alert did not successfully save. Please try again later.
Guillermo L. Monroy, Jinhong Kim, Alexander Ho, Andrey Mironov, Farzana R. Zaki, Darold R. Spillman Jr., Gabrielle Choo-Kang, Jungeun Won, Peter P. Sun, Edita Aksamitiene, Marina Marjanovic, Eric J. Chaney, Thanh Huong Nguyen, J. Gary Eden, Stephen A. Boppart, "Microplasma exposure as a novel therapeutic treatment for otitis media demonstrated in a pre-clinical chinchilla model," Proc. SPIE PC12358, Photonic Diagnosis, Monitoring, Prevention, and Treatment of Infections and Inflammatory Diseases 2023, PC1235809 (17 March 2023); https://doi.org/10.1117/12.2648469